"10.1371_journal.pone.0115476","plos one","2015-01-28T00:00:00Z","Surender Khurana; Elizabeth M Coyle; Jody Manischewitz; Lisa R King; Glenn Ishioka; Jeff Alexander; Jon Smith; Marc Gurwith; Hana Golding","Division of Viral products, Center for Biologics Evaluation and Research (CBER), Food and Drug Administration (FDA), Silver Spring, Maryland, United States of America, 20903; PaxVax, San Diego, CA, United States of America, 92121; PaxVax, Redwood City, CA, United States of America, 94063","Conceived and designed the experiments: SK HG. Performed the experiments: SK EC LK JM. Analyzed the data: SK EC LK JM HG. Contributed reagents/materials/analysis tools: SK EC JM LK GI JA JS MG HG. Wrote the paper: SK MG HG.","The authors have the following interests: Co-authors Glenn Ishioka, Jeff Alexander, Jon Smith and Marc Gurwith are employed by PaxVax and also own PaxVax stock. JA is listed as an author on a pending U.S. patent application No. 12/847,767. Title: Adenoviral-based vectors. Wellcome Trust funded the development of the Ad4-H5 vector through Phase I clinical trial for PaxVax. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.","2015","01","Surender Khurana","SK",9,TRUE,2,4,5,3,TRUE,TRUE,FALSE,0,NA,FALSE
